Proliferation plays a critical role in
tumor growth when cell migration is essential to invasion. The effect of Ang III and Ang II was evaluated on these important processes. Changes in the migration potential of
prostate cancer cells were investigated using Wound Healing Test and a Transwell Migration Chamber with a 3 μm pore size. Cell proliferation was measured with a
BrdU Assay and Countess Automated Cell Counter, thus determining the influence of
angiotensins on
hormone-dependent (LNCaP) and
hormone-independent (DU-145) human
prostate cancer lines. The influence of Ang III and Ang II on classic receptors may be inhibited by
Losartan or
PD123319. Test
peptide modulation of the AT1 and AT2 receptors was examined by Western Blot and fluorescent immunocytochemistry. The results indicate that Ang III promotes the migration of both LNCaP and DU-145 lines, whereas Ang II stimulates this process only in
androgen-independent cells. Both
angiotensin peptides can induce
prostate cancer cell proliferation in a time- and dose-dependent manner. The obtained results show that Ang III and Ang II can modify the expression of classic receptors, particularly AT2. These results suggest that the investigated
peptide can modulate cell migration and proliferation in
prostate cancer cells.
Angiotensins probably have a greater influence on proliferation in the early-stage
prostate cancer model than
hormone-independent cell lines. Assume also that Ang II can enhance the migration tendency aggressive
prostate cancer cells, while Ang III does so more effective in non-metastatic cells.